PDCD1 and lung carcinoma: According to a study by Swami et al. which involved giving a niraparib plus pembrolizumab combination regime to stage IV lung cancer patients, PD-1 inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors may synergize to boost innate and adaptive anticancer immune responses.